Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 39 of 39 publications.

Pathak A, Weber MA, Poulos C, Cohen SA, DeBruin V, Kandzari DE. Impact of expected blood pressure reduction on patient preferences for pharmaceutical and renal denervation treatment. J Hypertens. 2024 Sep 18. doi: 10.1097/HJH.0000000000003872

Abtahi S, Pajouheshnia R, Duran CE, Riera-Arnau J, Gamba M, Alsina E, Hoxhaj V, Andersen M, Bartolini C, Kristiansen SB, Brown J, Hallgreen CE, Garcia-Poza P, Gardarsdottir H, Gini R, Girardi A, Holthuis E, Huerta C, Ibanez L, Limoncella G, Martin-Perez M, Paoletti O, Roberto G, Souverein P, Swart KMA, Wing K, Sturkenboom M, Klungel O. Impact of 2018 EU Risk minimisation measures and revised pregnancy prevention programme on utilisation and prescribing trends of medicinal products containing valproate: an interrupted time series study. Drug Saf. 2023 Jul;46(7):689-702. doi: 10.1007/s40264-023-01314-3

Johannes CB, Beachler DC, Layton JB, Danysh HE, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Post-authorization safety study of hospitalization for acute kidney injury in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting. Drug Saf. 2023 Feb 1;46(2):157-74. doi: 10.1007/s40264-022-01263-3

Danysh HE, Johannes CB, Beachler DC, Layton JB, Ziemiecki R, Arana A, Dinh J, Li L, Calingaert B, Pladevall-Vila M, Hunt PR, Chen H, Karlsson C, Johnsson K, Gilsenan A. Post-authorization safety studies of acute liver injury and severe complications of urinary tract infection in patients with type 2 diabetes exposed to dapagliflozin in a real-world setting. Drug Saf. 2023 Feb 1;46(2):175-93. doi: 10.1007/s40264-022-01262-4

Layton JB, Forns Guzman J, McQuay LJ, Danysh HE, Dempsey C, Anthony MS, Turner ME. Mortality in patients with Parkinson's disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study. Drug Saf. 2023 Feb 1;46(2):195-208. doi: 10.1007/s40264-022-01260-6

Abtahi S, Pajouheshnia R, Duran-Salinas C, Riera-Arnau J, Gamba M, Alsina E, Hallgreen CE, Limoncella G, Bartolini C, Holthuis E, Martin-Perez M, Brown J, Sturkenboom M, Klungel O, Other Lot Consortium Members of the Valproate study. Impact of 2018 EU risk minimisation measures and revised pregnancy prevention programme on utilisation and prescribing trends of valproates. Poster presented at the 21st International Society of Pharmacovigilance (ISoP) Annual Meeting 2022; September 20, 2022. Verona, Italy. [abstract] Drug Saf. 2022 Aug 29; 45:1312-3. doi: 10.1007/s40264-022-01219-7

Abtahi S, Pajouheshnia R, Duran-Salinas C, Riera-Arnau J, Gamba M, Alsina E, Hallgreen CE, Limoncella G, Bartolini C, Martin-Perez M, Brown J, Sturkenboom M, Klungel O, Other Lot4 Consortium Members of the Valproate study1. Impact of the 2018 pregnancy prevention program on the use of oral retinoids in childbearing age females in Europe. Presented at the 21st International Society of Pharmacovigilance (ISoP) Annual Meeting 2022; September 20, 2022. Verona, Italy. [abstract] Drug Saf. 2022 Aug 29; 45:1111-327. doi: 10.1007/s40264-022-01219-7

Beau-Lejdstrom R, Hong LS, Garcia de Albeniz X, Floricel F, Lorenzen J, Bonfitto F, Kalilani L, Loesch C, Luscombe G, Perez-Gutthann S, Mottet I, Foskett N. Incidence of acute renal failure in patients using Levetiracetam versus other antiseizure medications: a voluntary post-authorization safety study. Drug Saf. 2022 Jul;45(7):781-90. doi: 10.1007/s40264-022-01193-0

Ersbøll AK, Sengupta K, Pukkala E, Bolin K, Aas E, Emneus M, Ramey DR, Brady JE, Mines D, Aasbjerg K, Vestergaard C, Gislason G, Born AP, Kjærulff TM. Desloratadine exposure and incidence of seizure: a nordic post-authorization safety study using a new-user cohort study design, 2001-2015. Drug Saf. 2021 Nov;44(11):1231-42. doi: 10.1007/s40264-021-01106-7

Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, Phiri K, Enger C, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, Seeger JD, mirabegron PMR-PASS study group. Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: findings from a non-interventional, multinational, cohort study. Drug Saf. 2021 Aug;44(8):899-915. doi: 10.1007/s40264-021-01095-7

Ruigomez A, Plana E, Gilsenan A, Fortuny J, Cainzos-Achirica M, Flynn RWV, MacDonald TM, Garcia-Rodriguez L, Ziemiecki R, Andrews EB. Identification and validation of major cardiovascular events in the United Kingdom data sources included in a multi-database post-authorization safety study of prucalopride. Drug Saf. 2021 May;44(5):541-51. doi: 10.1007/s40264-021-01044-4

Wen X, van der Laan M, Wyss R, Platt RW, Pajouheshnia R, Schneeweiss S. Machine learning to optimize and automate confounding control in studies using high-dimensional healthcare data. Presented at the Virtual 2020 36th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020. [abstract] Drug Saf. 2020 Oct 15; 29(S3):384. doi: 10.1002/pds.5114

Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu E, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride in patients with chronic constipation: a multinational population-based cohort study. Drug Saf. 2019 Oct;42(10):1179-90. doi: 10.1007/s40264-019-00835-0

Fortuny J, Gilsenan A, Cainzos-Achirica M, Cantero OF, Flynn RWV, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Study design and cohort comparability in a study of major cardiovascular events in new users of prucalopride versus polyethylene glycol 3350. Drug Saf. 2019 Oct;47(10):1167-77. doi: 10.1007/s40264-019-00836-z

Regier DA, Sicsic J, Watson V. Choice certainty and deliberative thinking in discrete choice experiments. A theoretical and empirical investigation. J Econ Behav Organ. 2019 Aug;164:235-55. doi: 10.1016/j.jebo.2019.05.031

Delacretaz A, Lagares Santos P, Saigi Morgui N, Vandenberghe F, Glatard A, Gholam-Rezaee M, von Gunten A, Conus P, Eap CB. Influence of polygenic risk scores on lipid levels and dyslipidemia in a psychiatric population receiving weight gain-inducing psychotropic drugs. Pharmacogenet Genomics. 2017 Dec 1;27(12):464-72. doi: 10.1097/FPC.0000000000000313

Vinceti M, Filippini T, Violi F, Rothman KJ, Costanzini S, Malagoli C, Wise LA, Odone A, Signorelli C, Iacuzio L, Arcolin E, Mandrioli J, Fini N, Patti F, Lo Fermo S, Pietrini V, Teggi S, Ghermandi G, Scillieri R, Ledda C, Mauceri C, Sciacca S, Fiore M, Ferrante M. Pesticide exposure assessed through agricultural crop proximity and risk of amyotrophic lateral sclerosis. Environ Health. 2017 Aug 29;16(1):91. doi: 10.1186/s12940-017-0297-2

Vandenberghe F, Saigi-Morgui N, Delacretaz A, Quteineh L, Crettol S, Ansermot N, Gholam-Rezaee M, von Gunten A, Conus P, Eap CB. Prediction of early weight gain during psychotropic treatment using a combinatorial model with clinical and genetic markers. Pharmacogenet Genomics. 2016 Dec;26(12):547-57. doi: 10.1097/FPC.0000000000000249

Spoendlin J, Layton JB, Mundkur M, Meier C, Jick SS, Meier CR. The risk of Achilles or biceps tendon rupture in new statin users: a propensity score matched sequential cohort study. Drug Saf. 2016 Dec;39(12):1229-37.

Saigi-Morgui N, Vandenberghe F, Delacretaz A, Quteineh L, Gholamrezaee M, Aubry JM, von Gunten A, Kutalik Z, Conus P, Eap CB. Association of genetic risk scores with body mass index in Swiss psychiatric cohorts. Pharmacogenet Genomics. 2016 May;26(5):208-17. doi: 10.1097/FPC.0000000000000210

Arana A, Johannes CB, McQuay LJ, Varas-Lorenzo C, Fife D, Rothman KJ. Risk of out-of-hospital sudden cardiac death in users of domperidone, proton pump inhibitors, or metoclopramide: a population-based nested case-control study. Drug Saf. 2015 Dec;38(12):1187-99. doi: 10.1007/s40264-015-0338-0.

Quteineh L, Vandenberghe F, Saigi Morgui N, Delacretaz A, Choong E, Gholam-Rezaee M, Magistretti P, Bondolfi G, von Gunten A, Preisig M, Castelao E, Vollenweider P, Waeber G, Bochud M, Kutalik Z, Conus P, Eap CB. Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. Pharmacogenet Genomics. 2015 May;25(5):246-58. doi: 10.1097/FPC.0000000000000131

Swartz MD, Cai Y, Chan W, Symanski E, Mitchell LE, Danysh HE, Langlois PH, Lupo PJ. Air toxics and birth defects: a Bayesian hierarchical approach to evaluate multiple pollutants and spina bifida. Environ Health. 2015 Feb 9;14:16. doi: 10.1186/1476-069X-14-16

Scheurer ME, Danysh HE, Follen M, Lupo PJ. Association of traffic-related hazardous air pollutants and cervical dysplasia in an urban multiethnic population: a cross-sectional study. Environ Health. 2014 Jun 13;13(1):52. doi: 10.1186/1476-069X-13-52

Reichenpfader U, Gartlehner G, Morgan LC, Greenblatt A, Nussbaumer B, Hansen RA, Van Noord M, Lux L, Gaynes BN. Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a systematic review with network meta-analysis. Drug Saf. 2014 Jan;37(1):19-31. doi: 10.1007/s40264-013-0129-4

Casas L, Tischer C, Wouters IM, Torrent M, Gehring U, Garcia-Esteban R, Thiering E, Postma DS, de Jongste J, Smit HA, Borras-Santos A, Zock JP, Hyvarinen A, Heinrich J, Sunyer J. Early life microbial exposure and fractional exhaled nitric oxide in school-age children: a prospective birth cohort study. Environ Health. 2013 Dec 2;12:103. doi: 10.1186/1476-069X-12-103

Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, Gatta A, McCormick A, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Benichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N. Transplantation for acute liver failure in patients exposed to NSAIDs or Paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013 Feb 1;36(2):135-44.

Nieuwenhuijsen MJ, Dadvand P, Grellier J, Martinez D, Vrijheid M. Environmental risk factors of pregnancy outcomes: a summary of recent meta-analyses of epidemiological studies. Environ Health. 2013 Jan;12(6). doi: 10.1186/1476-069X-12-6

Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, Sturkenboom M, Perez-Gutthann S. Individual NSAIDS and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46.

Cobos A, Sánchez P, Aguado J, Carrasco JL. Methodological quality in pharmacogenetic studies with binary assessment of treatment response: a review. Pharmacogenet Genomics. 2011 May;21(5):243-50.

Vinceti M, Bonvicini F, Rothman KJ, Vescovi L, Wang FY. The relation between amyotrophic lateral sclerosis and inorganic selenium in drinking water: a population-based case-control study. Environ Health. 2010 Dec 1;9(Art. No. 77).

Arana A, Allen S, Burkowitz J, Fantoni V, Ghatnekar O, Rico MT, Vanhaverbeke N, Wentworth CE, Brosa M, Arellano FM. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation. Drug Saf. 2010 Jun;33(6):489-501.

Arana A, Wentworth CE, Arellano FM. Validity of the codes of suicidality in the THIN database. Drug Saf. 2010;19(12):1316-7.

Johannes CB, Ziyadeh N, Seeger JD, Tucker E, Reiter C, Faich G. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. Drug Saf. 2007 Aug 1;30(8):705-13.

Hartford CG, Petchel KS, Mickail H, Perez-Gutthann S, McHale M, Grana JM, Marquez P. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines. Drug Saf. 2006 Aug 1;29(8):657-73. doi: 10.2165/00002018-200629080-00003

Pladevall-Vila M, Williams K, Guyer H, Sadurni J, Falces C, Ribes A, Pare C, Brotons C, Gabriel R, Serrano-Rios M, Haffner S. The association between leptin and left ventricular hypertrophy: a population-based cross-sectional study. J Hypertens. 2003 Aug;21(8):1467-73.

Pladevall-Vila M, Guyer H, Yañez A, Sadurni J, Falces C, Planes A, Ribes A. Left ventricular mass is associated with fasting leptin in women but not in men. Poster presented at the International Society of Hypertension; June 2000. [abstract] J Hypertens. 18:S168.

Castellsague J, Perez GS, Garcia Rodriguez LA. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review. Drug Saf. 1998 Feb 1;18(2):117-23.

Brosnihan KB, Weddle D, Anthony MS, Heise C, Li P, Ferrario CM. Effects of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. J Hypertens. 1997 Jul;15(7):719-26.